Colorectal cancer is one of the most diagnosed and fatal cancer in China, which brings a heavy burden to the clinic and economy. Despite recent improvements to diagnosis and treatment, less than 20% of patients with newly diagnosed metastatic colorectal cancer survive more than 5 years. Drug resistance in advanced colorectal cancer (chemotherapy, targeted therapy, immunotherapy) remains a major issue to be addressed, which highlights the importance of overcoming drug resistance in colorectal cancer. Furthermore, with the advent of various new biological technologies including genome editing, liquid biopsy, organoid models, and artificial intelligence, it is tempting to expect how these technologies will broaden and revolutionize our understanding of drug resistance in colorectal cancer. Many basic and clinical studies are underway to identify novel predictive biomarkers to decipher and reverse drug resistance in colorectal cancer. However, more novel studies are still urgently warranted to further propel the progress of colorectal cancer.
This Research Topic aims to provide high-quality basic, translational, and clinical studies with respect to drug resistance in colorectal cancer setting. We welcome submissions focusing on, but not limited to, the following aspects:
• Novel biomarkers of drug resistance in colorectal cancer
• Underlying mechanisms of drug resistance in colorectal cancer
• Latest advances and applications of novel technologies and preclinical research models to facilitate the understanding of drug resistance in colorectal cancer
• Novel strategies to overcome the drug resistance in colorectal cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Colorectal cancer is one of the most diagnosed and fatal cancer in China, which brings a heavy burden to the clinic and economy. Despite recent improvements to diagnosis and treatment, less than 20% of patients with newly diagnosed metastatic colorectal cancer survive more than 5 years. Drug resistance in advanced colorectal cancer (chemotherapy, targeted therapy, immunotherapy) remains a major issue to be addressed, which highlights the importance of overcoming drug resistance in colorectal cancer. Furthermore, with the advent of various new biological technologies including genome editing, liquid biopsy, organoid models, and artificial intelligence, it is tempting to expect how these technologies will broaden and revolutionize our understanding of drug resistance in colorectal cancer. Many basic and clinical studies are underway to identify novel predictive biomarkers to decipher and reverse drug resistance in colorectal cancer. However, more novel studies are still urgently warranted to further propel the progress of colorectal cancer.
This Research Topic aims to provide high-quality basic, translational, and clinical studies with respect to drug resistance in colorectal cancer setting. We welcome submissions focusing on, but not limited to, the following aspects:
• Novel biomarkers of drug resistance in colorectal cancer
• Underlying mechanisms of drug resistance in colorectal cancer
• Latest advances and applications of novel technologies and preclinical research models to facilitate the understanding of drug resistance in colorectal cancer
• Novel strategies to overcome the drug resistance in colorectal cancer
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.